Table 1.
Baseline Characteristics of the Study Population
| Sex | |
| Men | 473 (95.9%) |
| Transgender women | 20 (4.1%) |
| Age, in years | 38 (17) |
| Ethnicity | |
| Spanish | 372 (75.5%) |
| Latin-American | 108 (21.9%) |
| Other | 13 (2.6%) |
| Tobacco consumption | |
| Active smoker | 28 (44.2%) |
| Former smoker | 30 (6.1%) |
| Never smoker | 238 (48.3%) |
| Unknown | 7 (1.4%) |
| HCV positive antibodies | 18 (3.7%) |
| Previous STI | 357 (70.4%) |
| Condyloma acuminate | 151 (30.6%) |
| Syphilis | 230 (46.7%) |
| Gonorrhoea | 79 (16.0%) |
| Chlamydia trachomatis infection | 36 (7.3%) |
| Received HPV vaccine before inclusion | 14 (2.8%) |
| Prior AIDS-defining illness | 74 (15.0% |
| Nadir CD4+ | 344.5 (268) |
| Nadir CD4+ below 200 cells/μL | 117 (23.7%) |
| CD4+ count at the time of HIV diagnosis | 667 (440) |
| Baseline HPV | |
| Any HR-HPV | 394 (79.9%) |
| HPV-16 | 170 (34.5%) |
| HPV-18 | 72 (14.6%) |
| pHR-HPV | 363 (73.6%) |
| Baseline cytology | |
| Normal cytology | 286 (58.0%) |
| LSIL cytology | 95 (19.3%) |
| HSIL cytology | 19 (3.9%) |
| ASCUS | 93 (18.9%) |
| Dysplasia at baseline | 122 (24.7%) |
| LSIL (AIN-1) | 70 (14.2%) |
| HSIL (AIN-2/3) | 50 (10.1%) |
| Anal SCC | 2 (0.4%) |
Qualitative variables are expressed as total numbers and percentages; quantitative variables are presented as medians and interquartile ranges.
AIDS, acquired immunodeficiency syndrome; AIN, anal intraepithelial neoplasia; ASCUS, atypical squamous cells of undetermined significance; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR-HPV, high-risk HPV; HSIL, high-grade squamous-intraepithelial lesion; LSIL, low-grade squamous-intraepithelial lesion; pHR-HPV, pooled high-oncogenic risk human papillomavirus; SCC, squamous cell carcinoma; STI, sexually transmitted infection.